M
Michael D. Radmacher
Researcher at Ohio State University
Publications - 77
Citations - 13454
Michael D. Radmacher is an academic researcher from Ohio State University. The author has contributed to research in topics: Leukemia & BAALC. The author has an hindex of 40, co-authored 77 publications receiving 12921 citations. Previous affiliations of Michael D. Radmacher include Duke University & Kenyon College.
Papers
More filters
Journal ArticleDOI
Molecular classification of cutaneous malignant melanoma by gene expression profiling
M. Bittner,Paul S. Meltzer,Yi Chen,Yong-hui Jiang,E. A. Seftor,Mary J.C. Hendrix,Michael D. Radmacher,Richard M. Simon,Zohar Yakhini,Amir Ben-Dor,Amir Ben-Dor,Nick Sampas,Edward R. Dougherty,Ena Wang,Francesco M. Marincola,C. Gooden,John Lueders,Arthur A. Glatfelter,P.C.A. Pollock,John D. Carpten,E. Gillanders,D. Leja,K. Dietrich,Christian Beaudry,Michael E. Berens,David S. Alberts,Vernon K. Sondak,Nicholas K. Hayward,J.M. Trent +28 more
TL;DR: Many genes underlying the classification of this subset of melanomas are differentially regulated in invasive melanomas that form primitive tubular networks in vitro, a feature of some highly aggressive metastatic melanomas.
Journal ArticleDOI
Gene-Expression Profiles in Hereditary Breast Cancer
Ingrid Hedenfalk,David Duggan,Yi Chen,Michael D. Radmacher,M. Bittner,Richard M. Simon,P. Meltzer,Barry A. Gusterson,Manel Esteller,O. P. Kallioniemi,Benjamin S. Wilfond,Åke Borg,J.M. Trent,Mark Raffeld,Zohar Yakhini,Amir Ben-Dor,Edward R. Dougherty,Juha Kononen,Lukas Bubendorf,W Fehrle,Stefania Pittaluga,Sofia Gruvberger,Niklas Loman,Oskar T. Johannsson,Håkan Olsson,Guido Sauter +25 more
TL;DR: Significantly different groups of genes are expressed by breast cancers with BRCA1 mutations and breast cancersWith BRCa2 mutations, the results suggest that a heritable mutation influences the gene-expression profile of the cancer.
Journal ArticleDOI
Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification
TL;DR: In this article, the authors address statistical issues that arise from the use of DNA microarrays for an important group of objectives that has been called "class prediction", which includes derivation of predictors of prognosis, response to therapy, or any phenotype or genotype defined independently of the gene expression profile.
COMMENTARY Pitfalls in the Use of DNA Microarray Data for Diagnostic and Prognostic Classification
TL;DR: Statistical issues that arise from the use of DNA microarrays for an important group of objectives that has been called “class prediction” are addressed, which includes derivation of predictors of prognosis, response to therapy, or any phenotype or genotype defined independently of the gene expression profile.
Journal ArticleDOI
IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
Guido Marcucci,Kati Maharry,Yue-Zhong Wu,Michael D. Radmacher,Krzysztof Mrózek,Dean Margeson,Kelsi B. Holland,Susan P. Whitman,Heiko Becker,Sebastian Schwind,Klaus H. Metzeler,Bayard L. Powell,Thomas H. Carter,Jonathan E. Kolitz,Meir Wetzler,Andrew J. Carroll,Maria R. Baer,Michael A. Caligiuri,Richard A. Larson,Clara D. Bloomfield +19 more
TL;DR: The R172 IDH2 mutations, previously unreported in AML, characterize a novel subset of CN-AML patients lacking other prognostic mutations and associate with unique gene- and microRNA-expression profiles that may lead to the discovery of novel, therapeutically targetable leukemogenic mechanisms.